IBIO iBio, Inc.
iBio, Inc. (IBIO) is expected to report earnings on September 28, 2026, after the market close. The consensus earnings estimate is a loss of $0.07 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -11.7% since its last earnings release on May 12, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About iBio, Inc.
Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.
Sector
Healthcare
Industry
Biotechnology